Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Eva SumMoritz RappPhilipp FröbelMarine Le ClechHarald DürrAnna Maria GiustiMario PerroDario SpezialeLeo KunzElena MeniettiPeter BrünkerUlrike HopferMartin LechmannAndrzej SobienieckiBirte AppeltRoberto AdelfioValeria NicoliniAnne Freimoser-GrundschoberWhitney JordaanSara LabianoFelix WeberThomas EmrichFrançois ChristenBirgit EssigPedro RomeroChristine TrumpfhellerPablo UmañaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
FAP-CD40 abrogates the systemic toxicity associated with nontargeted CD40 agonists. This enables administration of high doses, essential for overcoming CD40 sink effects and inducing antitumor immunity. Consequently, FAP-targeted CD40 agonism represents a promising strategy to exploit the full potential of CD40 signaling for CIT.